DOLUTEGRAVIR efficacy in HIV infected patients

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

BACKGROUND Little is known about the applicability of dual treatments based on integrase inhibitors. We explored the combination of lamivudine + dolutegravir as an option when switching from standard cART in virologically suppressed patients. METHODS In this prospective cohort we enrolled patients previously switched to 3TC + DTG who were 18 years or older, with no previous resistance mutatio...

Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients

AIM Dolutegravir is the newest integrase inhibitor approved for HIV treatment and has demonstrated potent antiviral activity in patient populations with a broad range of treatment experience. This analysis aimed to characterize the population pharmacokinetics of dolutegravir in treatment-naive patients and to evaluate the influence of patient covariates. METHODS A population pharmacokinetic m...

Dolutegravir Monotherapy in HIV-Infected Naive Patients With <100,000 Copies/mL HIV RNA Load.

Dolutegravir-induced colitis in an HIV-infected patient.

Sir, Many of the gastrointestinal (GI) conditions associated with HIV disease have become much less frequent over the past two decades. Diarrhoea from opportunistic infections has become less common, and HIV-associated diarrhoea is now more often due to non-infectious causes such as ART-related adverse events and HIV enteropathy. Diarrhoea associated with ART is most commonly caused by PIs, whi...

Dolutegravir-based anti-retroviral therapy is effective and safe in HIV–infected paediatric patients

BACKGROUND Treatment of HIV infection in adolescents is challenging due to long duration of therapy and poor adherence. Recently, the integrase strand transfer inhibitor dolutegravir (DTG) has been approved for the use in adolescents with HIV, but evidence in clinical practice is very limited. METHODS We describe six cases of HIV-infected children/adolescents successfully treated with DTG-bas...